The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

See what infectious disease doctors have to say as government officials appear poised to scale back COVID vaccines and the ...

Federal health agencies were alerted in February 2021 to “large reports of myocarditis” in young people who received the Pfizer vaccine, but waited until late June to adjust the ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine with age restrictions after a six-week delay. The brand name is Nuvaxovid. Photo courtesy Novavax May 18 (UPI ...

The U.S. FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for older adults and those aged 12 to 64 at risk of severe illness. Despite missed deadlines and regulatory challenges, the approval is ...